Bio-Rad Laboratories, Inc. Profile Avatar - Palmy Investing

Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. Th…
Medical - Devices
US, Hercules [HQ]

FA

Fundamental Analysis · Most Recent Quarter

It is important to understand the FA Algorithm and the criterias before valuing it as a top-tier resource.

Read Rationale
Framework:
Valuation 43% Somewhat Weak
Profitability n.A. n.A.
Fin. Growth 67% Positive
Leverage & Liquidity 17% Weak
Per Share Metrics 33% Weak
Fin. Health n.A. n.A.
Fundamentals

Valuation

Metric Q4 Q1 Δ in %
EV/EBITDA 55.99 106.54 68.30
Graham Fair Price 7.64 310.06 288.04
PEG 1945.82 0.58 0.03
Price/Book 0.42 1.07 1.06
Price/Cash Flow 39.14 333.36 239.59
Prices/Earnings -5.28 6.30 6.65
Price/Sales 15.96 15.83 13.65
Price/FCF 39.14 333.36 239.59
Naive Interpretation member
01 - Valuation · Somewhat Weak
Fundamentals

Profitability

Metric Q4 Q1 Δ in %
Gross Profit Margin -0.50 0.53 0.54
Operating Margin -40.69 0.09 0.14
ROA 7.08 0.03 0.03
ROE 0.04 0.04 6.02
ROIC < 0.005 < 0.005 -50.60
Naive Interpretation member
02 - Profitability · Not Interpreted
Fundamentals

Financial Growth

Metric Q4 Q1 Δ in %
Debt QOQ < 0.005 0.17 -97.45
Dividends QOQ 0.00 0.00 0.00
EBIT QOQ 0.08 -0.47 522.33
EPS QOQ 2.33 0.11 -95.37
FCF QOQ -0.28 -0.25 8.67
Revenue QOQ 0.08 -0.10 33.09
Naive Interpretation member
03 - Financial Growth · Positive
Fundamentals

Leverage & Liquidity

Metric Q4 Q1 Δ in %
Assets Turnover n.A. n.A. n.A.
Days Inventory Outstanding (DIO) 222.80 247.94 11.28
Days Sales Outstanding (DSO) 66.18 67.72 2.32
Inventory Turnover 0.40 0.36 -10.14
Debt/Capitalization 0.12 0.12 -3.04
Quick Ratio 4.04 4.53 12.00
Naive Interpretation member
04 - Leverage & Liquidity · Weak
Fundamentals

Per Share Metrics

Metric Q4 Q1 Δ in %
Book Value 303.60 317.38 4.54
Cash 56.02 57.90 3.37
Capex -1.47 -1.41 3.98
Free Cash Flow 1.35 1.02 -24.55
Revenue 23.66 21.42 -9.47
Naive Interpretation member
05 - Per Share Metrics · Weak
Fundamentals

Financial Health

Metric Q4 Q1 Δ in %
Current Ratio 5.83 6.57 12.62
Debt/Assets n.A. n.A. n.A.
Debt/Equity n.A. n.A. n.A.
Net Debt/EBITDA 6.64 9.68 45.72
Naive Interpretation Member
06 - Financial Health · Bad
Rating